Oragenics (OGEN) 10-Q 15 Nov 21 2021 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2021	Nov. 12, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2021
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	001-32188
Entity Registrant Name	ORAGENICS INC
Entity Central Index Key	0001174940
Entity Tax Identification Number	59-3410522
Entity Incorporation, State or Country Code	FL
Entity Address, Address Line One	4902 Eisenhower Blvd.
Entity Address, Address Line Two	Suite 125
Entity Address, City or Town	Tampa
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33634
City Area Code	813
Local Phone Number	286-7900
Title of 12(b) Security	Common Stock
Trading Symbol	OGEN
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		116,394,806

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 29,948,892	$ 17,639,575
Prepaid expenses and other current assets	586,519	343,106
Total current assets	30,535,411	17,982,681
Property and equipment, net	32,704	42,713
Operating lease right-of-use assets	523,143	655,138
Total assets	31,091,258	18,680,532
Current liabilities:
Accounts payable and accrued expenses	1,523,197	937,020
Short-term notes payable	482,258	228,227
Operating lease liabilities	190,181	176,900
Total current liabilities	2,195,636	1,342,147
Long-term liabilities:
Operating lease liabilities	349,199	493,790
Total long-term liabilities	349,199	493,790
Shareholders’ equity:
Preferred stock, no par value; 50,000,000 shares authorized; 9,417,000 and 9,417,000 Series A shares, 6,600,000 and 6,600,000 Series B shares, -0- and 133.483 Series C shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively	2,656,713	7,174,854
Common stock, $0.001 par value; 200,000,000 shares authorized; 116,394,806 and 91,766,928 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively	116,395	91,767
Additional paid-in capital	194,754,867	164,022,957
Accumulated deficit	(168,981,552)	(154,444,983)
Total shareholders’ equity	28,546,423	16,844,595
Total liabilities and shareholders’ equity	$ 31,091,258	$ 18,680,532

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Preferred stock, par value	$ 0	$ 0
Preferred stock, shares authorized	50,000,000	50,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	116,394,806	91,766,928
Common stock, shares outstanding	116,394,806	91,766,928
Series A Preferred Stock [Member]
Preferred stock, shares issued	9,417,000	9,417,000
Preferred stock, shares outstanding	9,417,000	9,417,000
Series B Preferred Stock [Member]
Preferred stock, shares issued	6,600,000	6,600,000
Preferred stock, shares outstanding	6,600,000	6,600,000
Series C Preferred Stock [Member]
Preferred stock, shares issued	0	133.483
Preferred stock, shares outstanding	0	133.483

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Operating expenses:
Research and development	$ 3,547,321	$ 3,498,361	$ 9,275,800	$ 18,755,013
General and administrative	847,134	1,010,006	4,194,103	3,337,422
Total operating expenses	4,394,455	4,508,367	13,469,903	22,092,435
Loss from operations	(4,394,455)	(4,508,367)	(13,469,903)	(22,092,435)
Other income (expense):
Interest income	17,760	16,292	62,047	77,302
Interest expense	(7,053)	(3,885)	(10,654)	(6,478)
Local business tax	2	(600)	(1,198)	(1,800)
Miscellaneous income			670	1,795
Total other income, net	10,709	11,807	50,865	70,819
Loss before income taxes	(4,383,746)	(4,496,560)	(13,419,038)	(22,021,616)
Income tax benefit
Net loss	$ (4,383,746)	$ (4,496,560)	$ (13,419,038)	$ (22,021,616)
Basic and diluted net loss per share	$ (0.04)	$ (0.08)	$ (0.12)	$ (0.42)
Shares used to compute basic and diluted net loss per share	116,262,938	59,670,038	111,748,586	52,706,277

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Preferred Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2019	$ 46,125	$ 6,513,396	$ 138,024,957	$ (127,352,826)	$ 17,231,652
Balance, shares at Dec. 31, 2019	46,124,803	16,017,113.941
Compensation expense relating to option issuances			865,110		865,110
Series C dividend		$ 661,458		(661,458)
Series C dividend, shares		19.542
Net loss				(5,187,760)	(5,187,760)
Balances at Mar. 31, 2020	$ 46,125	$ 7,174,854	138,890,067	(133,202,044)	12,909,002
Balance, shares at Mar. 31, 2020	46,124,803	16,017,133.483
Balance at Dec. 31, 2019	$ 46,125	$ 6,513,396	138,024,957	(127,352,826)	17,231,652
Balance, shares at Dec. 31, 2019	46,124,803	16,017,113.941
Net loss					(22,021,616)
Balances at Sep. 30, 2020	$ 61,005	$ 7,174,854	152,440,386	(150,035,900)	9,640,345
Balance, shares at Sep. 30, 2020	61,004,917	16,017,133.483
Balance at Mar. 31, 2020	$ 46,125	$ 7,174,854	138,890,067	(133,202,044)	12,909,002
Balance, shares at Mar. 31, 2020	46,124,803	16,017,133.483
Compensation expense relating to option issuances			157,145		157,145
Issuance of common stock from warrant exercise	$ 38		28,462		28,500
Issuance of common stock from warrant exercise, shares	38,000
Issuance of common stock and warrants for the acquisition of Noachis Terra	$ 9,200		8,021,499		8,030,699
Issuance of common stock and warrants for the acquisition of noachis terra, shares	9,200,000
Net loss				(12,337,296)	(12,337,296)
Balances at Jun. 30, 2020	$ 55,363	$ 7,174,854	147,097,173	(145,539,340)	8,788,050
Balance, shares at Jun. 30, 2020	55,362,803	16,017,133.483
Compensation expense relating to option issuances			194,953		194,953
Issuance of common stock from warrant exercise	$ 5,642		5,148,260		5,153,902
Issuance of common stock from warrant exercise, shares	5,642,114
Net loss				(4,496,560)	(4,496,560)
Balances at Sep. 30, 2020	$ 61,005	$ 7,174,854	152,440,386	(150,035,900)	9,640,345
Balance, shares at Sep. 30, 2020	61,004,917	16,017,133.483
Balance at Dec. 31, 2020	$ 91,767	$ 7,174,854	164,022,957	(154,444,983)	16,844,595
Balance, shares at Dec. 31, 2020	91,766,928	16,017,133.483
Compensation expense relating to option issuances			1,123,761		1,123,761
Series C dividend		$ 1,117,531		(1,117,531)
Series C dividend, shares		33.016
Series C redemption		$ (5,635,672)			(5,635,672)
Series C redemption, shares		(166.499)
ATM offering - net of expenses	$ 21,399		26,654,993		26,676,392
ATM offering - net of expenses, shares	21,398,765
Issuance of common stock from warrant exercise	$ 2,472		2,258,864		2,261,336
Issuance of common stock from warrant exercise, shares	2,472,573
Net loss				(5,219,945)	(5,219,945)
Balances at Mar. 31, 2021	$ 115,638	$ 2,656,713	194,060,575	(160,782,459)	36,050,467
Balance, shares at Mar. 31, 2021	115,638,266	16,017,000
Balance at Dec. 31, 2020	$ 91,767	$ 7,174,854	164,022,957	(154,444,983)	$ 16,844,595
Balance, shares at Dec. 31, 2020	91,766,928	16,017,133.483
Issuance of common stock from option exercise, shares	756,540				756,540
Net loss					$ (13,419,038)
Balances at Sep. 30, 2021	$ 116,395	$ 2,656,713	194,754,867	(168,981,552)	28,546,423
Balance, shares at Sep. 30, 2021	116,394,806	16,017,000
Balance at Mar. 31, 2021	$ 115,638	$ 2,656,713	194,060,575	(160,782,459)	36,050,467
Balance, shares at Mar. 31, 2021	115,638,266	16,017,000
Compensation expense relating to option issuances			231,140		231,140
Issuance of common stock from option exercise	$ 557		266,583		267,140
Issuance of common stock from option exercise, shares	556,540
Net loss				(3,815,347)	(3,815,347)
Balances at Jun. 30, 2021	$ 116,195	$ 2,656,713	194,558,298	(164,597,806)	32,733,400
Balance, shares at Jun. 30, 2021	116,194,806	16,017,000
Compensation expense relating to option issuances			100,769		100,769
Issuance of common stock from option exercise	$ 200		95,800		96,000
Issuance of common stock from option exercise, shares	200,000
Net loss				(4,383,746)	(4,383,746)
Balances at Sep. 30, 2021	$ 116,395	$ 2,656,713	$ 194,754,867	$ (168,981,552)	$ 28,546,423
Balance, shares at Sep. 30, 2021	116,394,806	16,017,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities:
Net loss	$ (13,419,038)	$ (22,021,616)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	34,817	38,847
Stock-based compensation expense	1,455,670	1,217,208
Stock issued for purchase of Noachis Terra		8,030,699
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(243,413)	498,200
Accounts payable and accrued expenses	586,177	(1,084,621)
Net cash used in operating activities	(11,585,787)	(13,321,283)
Cash flows from investing activities:
Purchase of property and equipment	(24,123)
Net cash used in investing activities	(24,123)
Cash flows from financing activities:
Borrowings under short-term notes payable	600,169	132,088
Payments on short-term notes payable	(346,138)	(217,588)
Redemption of Series C Preferred stock	(5,635,672)
Proceeds from issuance of common stock for stock option exercise	363,140
Proceeds from issuance of common stock for warrant exercise	2,261,336	5,182,402
Net proceeds from issuance of common stock	26,676,392
Net cash provided by financing activities	23,919,227	5,096,902
Net increase (decrease) in cash and cash equivalents	12,309,317	(8,224,381)
Cash and cash equivalents at beginning of period	17,639,575	18,267,994
Cash and cash equivalents at end of period	29,948,892	10,043,613
Supplemental disclosure of cash flow information:
Interest paid	10,654	4,245
Non-cash investing and financing activities:
Stock dividend on Series C preferred stock	$ 1,117,531	$ 661,458

Organization

Organization	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	1. Organization Oragenics, Inc. (formerly known as Oragen, Inc.) (the “Company” or “we”) was incorporated in November, 1996; however, operating activity did not commence until 1999. We are focused on the creation of the Terra CoV-2 immunization product candidate to combat the novel coronavirus pandemic and the further development of effective treatments for novel antibiotics against infectious disease.

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	2. Basis of Presentation The accompanying unaudited interim consolidated financial statements as of September 30, 2021 and December 31, 2020 (audited) and three and nine months ended September 30, 2021 and 2020, have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) for interim consolidated financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by US GAAP for complete consolidated financial statements. In the opinion of management, the accompanying consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the financial condition, results of operations and cash flows for the periods presented. The results of operations for the interim period ended September 30, 2021, are not necessarily indicative of the results of operations that may be expected for the year ended December 31, 2021, or any future period. These consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2020, which are included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2021. The Company has incurred recurring losses and negative cash flows from operations since inception. To date, the Company has not generated significant revenues from operations. The Company incurred a net loss of $ 13,419,038 11,585,787 168,981,552 The Company expects to incur substantial expenditures to further develop its technologies. The Company believes the working capital at September 30, 2021 will be sufficient to meet the business objectives as presently structured into the third quarter of 2022. The Company’s ability to continue operations after its current cash resources are exhausted depends on its ability to obtain additional financing or achieve profitable operations, as to which no assurances can be given. Cash requirements may vary materially from those now planned because of changes in the Company’s focus and direction of its research and development programs, competitive and technical advances, or other developments. Additional financing will be required to continue operations after the Company exhausts its current cash resources and to continue its long-term plans for clinical trials and new product development. There can be no assurance that any such financing can be realized by the Company, or if realized, what the terms thereof may be, or that any amount that the Company is able to raise will be adequate to support the Company’s working capital requirements until it achieves profitable operations. The Company intends to seek additional funding through sublicensing arrangements, joint venturing or partnering, sales of rights to technology, government grants and public or private financings. The Company’s future success depends on its ability to raise capital and ultimately generate revenue and attain profitability. The Company cannot be certain that additional capital, whether through selling additional debt or equity securities or obtaining a line of credit or other loan, will be available to it or, if available, will be on terms acceptable to the Company. If the Company issues additional securities to raise funds, these securities may have rights, preferences, or privileges senior to those of its common stock, and the Company’s current shareholders may experience dilution. If the Company is unable to obtain funds when needed or on acceptable terms, the Company may be required to curtail its current development programs, cut operating costs and forego future development and other opportunities.

Significant Accounting Policies

Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Significant Accounting Policies	3. Significant Accounting Policies Basis of Consolidation The consolidated financial statements include the accounts of Oragenics, Inc. and our wholly-owned subsidiary Noachis Terra, Inc. All intercompany balances and transactions have been eliminated. New Accounting Standards There are no additional accounting pronouncements issued or effective during the three and nine months ended September 30, 2021, that have had, or are expected to have, a material impact on our consolidated financial statements. Recently Issued Accounting Pronouncements Income Taxes In December 2019, the FASB issued ASU No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company’s adoption of the provisions of ASU No. 2019-12, did not have an impact on its consolidated financial statements and related disclosures. Use of Estimates The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. The principal areas of estimation reflected in the consolidated financial statements are stock-based compensation, and valuation of warrants. Stock-Based Payment Arrangements Generally, all forms of stock-based payments, including stock option grants, and warrants are measured at their fair value on the awards’ grant date using a Black-Scholes pricing model. Stock-based compensation awards issued to non-employees for services rendered are recorded at the fair value of the stock-based payment. The expense resulting from stock-based payments are recorded in research and development expense or general and administrative expense in the consolidated statement of operations, depending on the nature of the services provided. Stock-based payment expense is recorded over the requisite service period in which the grantee provides services to us. To the extent the stock option grants, warrants, or restricted stock grants do not vest at the grant date they are subject to forfeiture. Stock-Based Compensation US GAAP requires all stock-based payments to employees, including grants of employee stock options, to be recognized in the consolidated financial statements based on their fair values as of the grant date. Stock-based compensation expense is recorded over the requisite service period in which the grantee provides services to us, to the extent the options do not vest at the grant date and are subject to forfeiture. For performance-based awards that do not include market-based conditions, we record share-based compensation expense only when the performance-based milestone is deemed probable of achievement. We utilize both quantitative and qualitative criteria to judge whether milestones are probable of achievement. For awards with market-based performance conditions, we recognize the grant-date fair value of the award over the derived service period regardless of whether the underlying performance condition is met. In connection with adopting ASU 2016-09, the Company made an accounting policy election to account for forfeitures in compensation expense as they occur. Warrants The Company used the Black Scholes Option Pricing Model in calculating the relative fair value of any warrants that have been issued. Net Loss Per Share During all periods presented, the Company had securities outstanding that could potentially dilute basic earnings per share in the future but were excluded from the computation of diluted net loss per share, as their effect would have been antidilutive because the Company reported a net loss for all periods presented. Basic and diluted net loss per share amounts are the same for the periods presented. Net loss per share is computed using the weighted average number of shares of common stock outstanding. Concentrations Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash accounts in commercial banks, which may, at times, exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents. As of September 30, 2021, the uninsured portion of this balance was $ 29,698,892 17,389,575

Stock-based Compensation

Stock-based Compensation	9 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Stock-based Compensation	5. Stock-based Compensation The Company recognized stock-based compensation on all employee and non-employee awards as follows: Schedule of Stock-based Compensation Expense Recognized For the Three Months Ended September 30, 2021 For the Three Months Ended September 30, 2020 For the Nine Months Ended September 30, 2021 For the Nine Months Ended September 30, 2020 Research and development $ 38,946 $ 46,584 $ 118,634 $ 194,431 General and administrative 61,823 148,369 1,337,036 1,022,777 Total Stock-based compensation $ 100,769 $ 194,953 $ 1,455,670 $ 1,217,208 The following table summarizes the stock option activity during the nine months ended September 30, 2021: Summary of Stock Option Activity Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (In Years) Aggregate Intrinsic Value (1) Outstanding at December 31, 2020 5,801,349 $ 0.90 8.52 $ 2,773 Granted 1,720,000 $ 1.19 — $ — Exercised (756,540 ) $ 0.48 — $ — Forfeited (512,967 ) $ 1.65 — $ — Outstanding at September 30, 2021 6,251,842 $ 1.00 7.32 $ 460,844 Exercisable at September 30, 2021 5,396,839 $ 1.02 7.10 $ 410,777 (1) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock option awards and the closing market price of our common stock as of December 31, 2020 and September 30, 2021, respectively. Total unrecognized compensation cost related to unvested stock options was $ 414,571 two years As of September 30, 2021, 1,000,868 Each executive officer and non-employee director receiving equity-based awards is subject to a minimum dollar value stock ownership holding requirement with respect to the awards received as well as all prior equity awards under the Plan which requirements are intended to align the ability to sell shares with the performance of the Company’s stock price. The executive officer recipients each have a minimum dollar value stock ownership holding requirement threshold equal to two times (2x) their then base salaries below which dollar threshold they would be precluded from selling any shares of Company stock obtained from the Company under its Plan. Also, the non-employee directors are each subject to a minimum dollar value stock ownership holding requirement threshold equal to six times the annual Board retainer ($ 270,000 The Company entered into a separation agreement with its former chief executive officer which provided for severance payments as contemplated by his employment agreement and (i) accelerated the vesting of certain outstanding option awards; and (ii) extended the time for the exercise of certain vested options for one year from the date of separation. The former executive exercised options to acquire 400,000

Warrants

Warrants	9 Months Ended
	Sep. 30, 2021
Warrants
Warrants	6. Warrants During the three months ended March 31, 2021, the Company issued an additional 2,472,573 360,000 1.00 2,112,573 0.90 2,261,336 During the three months ended September 30, 2020, the Company issued an additional 5,642,114 760,000 1.00 4,882,114 0.90 5,153,902 On May 14, 2020 warrants to acquire 9,545,334 On May 1, 2020, the Company issued warrants to acquire 9,200,000 1.25 five-year A summary of warrant activity for the year ended December 31, 2020 and the nine months ended September 30, 2021 is as follows: Schedule of Warrants Activity Warrants Weighted Average Price Balance - December 31, 2019 26,538,593 $ 1.08 Granted 9,200,000 1.25 Exercised (5,680,114 ) 0.91 Expired (9,545,334 ) 0.75 Balance - December 31, 2020 20,513,145 1.36 Granted — — Exercised (2,472,573 ) 0.91 Expired — — Balance - September 30, 2021 18,040,572 $ 1.42 The warrants outstanding as of September 30, 2021 are as follows: Schedule of Warrants Outstanding Exercise Price Warrants Outstanding Expiration Date $ 3.10 48,387 9/19/2022 $ 2.00 900,000 4/10/2023 $ 3.10 462,106 5/10/2024 $ 3.10 602,414 7/25/2024 $ 3.10 1,064,518 11/8/2024 $ 1.00 3,174,500 7/17/2025 $ 0.90 2,588,647 3/25/2024 $ 1.25 9,200,000 5/1/2025 18,040,572 All outstanding warrants are classified as equity on the Company’s Consolidated Balance Sheets.

Short-Term Notes Payable

Short-Term Notes Payable	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Short-Term Notes Payable	7. Short-Term Notes Payable As of September 30, 2021 and December 31, 2020, the Company had $ 482,258 228,227 Products Liability Insurance On March 10, 2019, the Company entered into a short-term note payable for $ 17,688 5.69% 11-month period February 14, 2020 Directors’ and Officers’ Insurance On July 24, 2021, the Company entered into a short-term note payable for $ 600,169 5.34% 10-month period May 24, 2022 On July 24, 2020, the Company entered into a short-term note payable for $ 413,784 5.39% 11-month period June 28, 2021

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies (i) twenty percent ( 20% 0.90 45% 1.00 As a result of warrant exercises during the three months ended March 31, 2021, 2,472,573 360,000 1.00 2,112,573 0.90 , and the Company paid $ 542,263 NIH License Through NTI, the Company is a party to a Patent License and Biological Materials License Agreement (the “License Agreement” or “NIH License”), dated March 23, 2020, with the United States Department of Health and Human Services (the “HHS”), as represented by the National Institute of Allergy and Infectious Diseases (“NIAID”), an Institute within the National Institutes of Health (“NIH”). Under the terms of the License Agreement, we hold a nonexclusive, worldwide license to certain specified patent rights (including patent applications, provisional patent applications and Patent Cooperation Treaty (“PCT”) patent applications) and biological materials relating to the use of pre-fusion coronavirus spike proteins to exploit products (“Licensed Products”) and practice processes (“Licensed Processes”) that are covered by the licensed patent rights and biological materials for the purpose of developing and commercializing a vaccine product candidate for SARS-CoV-2. Under the terms of the License Agreement, the NIAID is entitled to receive a non-creditable, nonrefundable upfront license issue royalty of $ 30,000 11,739 The License Agreement will expire upon (a) twenty ( 20 NRC License On July 26, 2021, the Company entered into a non-exclusive Technology License Agreement (the “License Agreement”) with the National Research Council of Canada (“NRC”) pursuant to which the NRC grants to the Company a license to use NRC’s inventions, patents, trade secrets, know-how, copyright, biological material, designs, and/or technical information created by or on behalf of the NRC (the “NRC Technologies”) relating to the derivatives of CHO 2353 TM ”) As consideration for the grant of the license, the Company will pay to the NRC an annual (low five digits) license fee, with the initial portion of the fee covering the first three years of the license. Additionally, we will pay certain milestone payments (a) upon transfer of each Stable Cell listed in the Agreement and (b) with regard to each of the first three Products, (i) upon submission of the Investigational New Drug application (IND) related thereto, (ii) upon dosing the first patient in a Phase 1 or Phase 2 clinical trial, (iii) upon dosing the first patient in a Phase 3 clinical trial and (iv) upon first regulatory approval. Milestone payments range from the low five digits to high six digits. In addition, Oragenics will pay a low single-digit royalty to the NRC for the sale of Products, based on sales revenue, commencing after the first commercial sale. Pursuant to the License Agreement, the NRC is required to bear the responsibility and pay the costs to obtain and maintain patents related to the NRC Technologies in the U.S., Canada, Brazil, European Union, Japan, South Korea, Singapore, Australia, China, and India, and the NRC shall use reasonable efforts to obtain and maintain those patents. Additional countries may be requested by us, in which event, the NRC will file and maintain such patents, at our expense. Pursuant to the License Agreement, we are required to indemnify and hold the NRC and its employees and agents harmless from and against all liability and damages in connection with or arising out of all claims, demands, losses, damages, costs including solicitor and client costs, actions, suits or proceedings brought by any third party that are in any manner based upon, arising out of, related to, occasioned by, or attributable to the manufacturing, distribution, shipment, offering for sale, sale, or use of Products, services based on the NRC Technologies and product liability and infringement of intellectual property rights other than copyright, if any, licensed under the License Agreement. Unless terminated earlier, the License Agreement will terminate twenty (20) years from the effective date of the License Agreement. Either party may terminate the License Agreement, by giving written notice to the other party, if the other party defaults or is in breach of the License Agreement, provided that if the defaulting party cures the breach within 60 days after the notice is given, the License Agreement shall continue in full force and effect. The NRC may terminate the License Agreement if the Company becomes bankrupt, or insolvent, or has a receiver appointed to continue its operations, or passes a resolution for winding up. The License Agreement contains customary confidentiality obligations. In addition, in connection with the initiative to develop its vaccine, we also previously entered into a material transfer agreement with the NRC for SARS-CoV-2 trimeric spike protein Wuhan variant and SARS-CoV-2 trimeric spike protein South African variant to move forward with pre-clinical testing. The Lantibiotic ECC On September 22, 2021, the Company and Eleszto Genetika, Inc. mutually terminated the amended and restated worldwide exclusive channel collaboration agreement dated March 1, 2021 (the “Lantibiotic ECC”) pursuant to which the Company was pursuing the development of OG716 as a lead product candidate for the treatment of C. diff As a result of the mutual termination of the Lantibiotic ECC, the Company will cease pre-clinical development of its product candidate OG716 and other compounds covered by the Lantibiotic ECC, all licenses provided pursuant to the Lantibiotic ECC between the parties were terminated and there are no continuing obligations between the parties, except as to confidentiality. The Company made no payments to EGI in connection with the mutual termination. Each party retained all right and title to their own respective intellectual property. The Company will focus on its continuing independent research and development efforts relative to lantibiotics in order to identify new compounds to pursue. Leases The Company’s Alachua facility is being leased from a real estate developer for a term of five years beginning in December 2019. Under the amended lease agreement, the rental payments range from $ 12,870 13,338 In November of 2016, the Company entered into an amendment for the leased office space for corporate personnel located in Tampa, FL. The amended lease is for approximately 2,207 4,138 4,392 February 29, 2020 three years 4,524 4,800 Supplemental balance sheet information related to leases is as follows: Schedule of Supplemental Balance Sheet Information Related to Leases September 30, 2021 December 31, 2020 Weighted Average Remaining Lease Term In Years Operating leases 2.71 3.46 Weighted Average Discount Rate Operating leases 5.70 % 5.70 % Maturities of operating lease liabilities are as follows: Schedule of Maturities of Operating Lease Liabilities Year ended December 31: 2021 $ 53,059 2022 217,379 2023 169,656 2024 146,719 Total $ 586,813 Less: Imputed interest (47,433 ) Present value of lease liabilities $ 539,380 The cost component of operating leases is as follows: Schedule of Cost Component of Operating Leases For the Nine For The Nine Operating lease cost $ 171,040 $ 169,126 Short-term lease cost 1,159 1,839 Total lease cost $ 172,199 $ 170,965 Supplemental cash flow information related to operating leases is as follows: Schedule of Supplemental Cash Flow Information Related to Operating Leases For the Nine For The Nine Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 170,354 $ 169,264

Shareholders_ Equity

Shareholders’ Equity	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Shareholders’ Equity	9. Shareholders’ Equity Common Stock During the nine months ended September 30, 2021, the Company issued 756,540 363,140 During the three months ended March 31, 2021, the Company issued an aggregate of 23,871,338 21,398,765 27.8 2,472,573 2.3 The Company did not issue any shares of common stock pursuant to the ATM Program during the three months ended September 30, 2021 Preferred Stock Series C Preferred Stock Dividend and Redemption During the three months ended March 31, 2021, the Company provided a notice of redemption, to the holder of the Company’s Series C Preferred Stock to redeem all outstanding Series C Preferred Stock (which included the dividend of 26.697 5.6

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Consolidation	Basis of Consolidation The consolidated financial statements include the accounts of Oragenics, Inc. and our wholly-owned subsidiary Noachis Terra, Inc. All intercompany balances and transactions have been eliminated.
New Accounting Standards	New Accounting Standards There are no additional accounting pronouncements issued or effective during the three and nine months ended September 30, 2021, that have had, or are expected to have, a material impact on our consolidated financial statements.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements Income Taxes In December 2019, the FASB issued ASU No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company’s adoption of the provisions of ASU No. 2019-12, did not have an impact on its consolidated financial statements and related disclosures.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. The principal areas of estimation reflected in the consolidated financial statements are stock-based compensation, and valuation of warrants.
Stock-Based Payment Arrangements	Stock-Based Payment Arrangements Generally, all forms of stock-based payments, including stock option grants, and warrants are measured at their fair value on the awards’ grant date using a Black-Scholes pricing model. Stock-based compensation awards issued to non-employees for services rendered are recorded at the fair value of the stock-based payment. The expense resulting from stock-based payments are recorded in research and development expense or general and administrative expense in the consolidated statement of operations, depending on the nature of the services provided. Stock-based payment expense is recorded over the requisite service period in which the grantee provides services to us. To the extent the stock option grants, warrants, or restricted stock grants do not vest at the grant date they are subject to forfeiture.
Stock-Based Compensation	Stock-Based Compensation US GAAP requires all stock-based payments to employees, including grants of employee stock options, to be recognized in the consolidated financial statements based on their fair values as of the grant date. Stock-based compensation expense is recorded over the requisite service period in which the grantee provides services to us, to the extent the options do not vest at the grant date and are subject to forfeiture. For performance-based awards that do not include market-based conditions, we record share-based compensation expense only when the performance-based milestone is deemed probable of achievement. We utilize both quantitative and qualitative criteria to judge whether milestones are probable of achievement. For awards with market-based performance conditions, we recognize the grant-date fair value of the award over the derived service period regardless of whether the underlying performance condition is met. In connection with adopting ASU 2016-09, the Company made an accounting policy election to account for forfeitures in compensation expense as they occur.
Warrants	Warrants The Company used the Black Scholes Option Pricing Model in calculating the relative fair value of any warrants that have been issued.
Net Loss Per Share	Net Loss Per Share During all periods presented, the Company had securities outstanding that could potentially dilute basic earnings per share in the future but were excluded from the computation of diluted net loss per share, as their effect would have been antidilutive because the Company reported a net loss for all periods presented. Basic and diluted net loss per share amounts are the same for the periods presented. Net loss per share is computed using the weighted average number of shares of common stock outstanding.
Concentrations	Concentrations Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash accounts in commercial banks, which may, at times, exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents. As of September 30, 2021, the uninsured portion of this balance was $ 29,698,892 17,389,575

Stock-based Compensation (Table

Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Schedule of Stock-based Compensation Expense Recognized	The Company recognized stock-based compensation on all employee and non-employee awards as follows: Schedule of Stock-based Compensation Expense Recognized For the Three Months Ended September 30, 2021 For the Three Months Ended September 30, 2020 For the Nine Months Ended September 30, 2021 For the Nine Months Ended September 30, 2020 Research and development $ 38,946 $ 46,584 $ 118,634 $ 194,431 General and administrative 61,823 148,369 1,337,036 1,022,777 Total Stock-based compensation $ 100,769 $ 194,953 $ 1,455,670 $ 1,217,208
Summary of Stock Option Activity	The following table summarizes the stock option activity during the nine months ended September 30, 2021: Summary of Stock Option Activity Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (In Years) Aggregate Intrinsic Value (1) Outstanding at December 31, 2020 5,801,349 $ 0.90 8.52 $ 2,773 Granted 1,720,000 $ 1.19 — $ — Exercised (756,540 ) $ 0.48 — $ — Forfeited (512,967 ) $ 1.65 — $ — Outstanding at September 30, 2021 6,251,842 $ 1.00 7.32 $ 460,844 Exercisable at September 30, 2021 5,396,839 $ 1.02 7.10 $ 410,777 (1) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock option awards and the closing market price of our common stock as of December 31, 2020 and September 30, 2021, respectively.

Warrants (Tables)

Warrants (Tables)	9 Months Ended
	Sep. 30, 2021
Warrants
Schedule of Warrants Activity	A summary of warrant activity for the year ended December 31, 2020 and the nine months ended September 30, 2021 is as follows: Schedule of Warrants Activity Warrants Weighted Average Price Balance - December 31, 2019 26,538,593 $ 1.08 Granted 9,200,000 1.25 Exercised (5,680,114 ) 0.91 Expired (9,545,334 ) 0.75 Balance - December 31, 2020 20,513,145 1.36 Granted — — Exercised (2,472,573 ) 0.91 Expired — — Balance - September 30, 2021 18,040,572 $ 1.42
Schedule of Warrants Outstanding	The warrants outstanding as of September 30, 2021 are as follows: Schedule of Warrants Outstanding Exercise Price Warrants Outstanding Expiration Date $ 3.10 48,387 9/19/2022 $ 2.00 900,000 4/10/2023 $ 3.10 462,106 5/10/2024 $ 3.10 602,414 7/25/2024 $ 3.10 1,064,518 11/8/2024 $ 1.00 3,174,500 7/17/2025 $ 0.90 2,588,647 3/25/2024 $ 1.25 9,200,000 5/1/2025 18,040,572

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Schedule of Supplemental Balance Sheet Information Related to Leases	Supplemental balance sheet information related to leases is as follows: Schedule of Supplemental Balance Sheet Information Related to Leases September 30, 2021 December 31, 2020 Weighted Average Remaining Lease Term In Years Operating leases 2.71 3.46 Weighted Average Discount Rate Operating leases 5.70 % 5.70 %
Schedule of Maturities of Operating Lease Liabilities	Maturities of operating lease liabilities are as follows: Schedule of Maturities of Operating Lease Liabilities Year ended December 31: 2021 $ 53,059 2022 217,379 2023 169,656 2024 146,719 Total $ 586,813 Less: Imputed interest (47,433 ) Present value of lease liabilities $ 539,380
Schedule of Cost Component of Operating Leases	The cost component of operating leases is as follows: Schedule of Cost Component of Operating Leases For the Nine For The Nine Operating lease cost $ 171,040 $ 169,126 Short-term lease cost 1,159 1,839 Total lease cost $ 172,199 $ 170,965
Schedule of Supplemental Cash Flow Information Related to Operating Leases	Supplemental cash flow information related to operating leases is as follows: Schedule of Supplemental Cash Flow Information Related to Operating Leases For the Nine For The Nine Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 170,354 $ 169,264

Basis of Presentation (Details

Basis of Presentation (Details Narrative) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Accounting Policies [Abstract]
Net loss	$ 4,383,746	$ 3,815,347	$ 5,219,945	$ 4,496,560	$ 12,337,296	$ 5,187,760	$ 13,419,038	$ 22,021,616
Cash used in operations							11,585,787	$ 13,321,283
Accumulated deficit	$ 168,981,552						$ 168,981,552		$ 154,444,983

Significant Accounting Polici_3

Significant Accounting Policies (Details Narrative) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Uninsured portion of balance	$ 29,698,892	$ 17,389,575

Schedule of Stock-based Compens

Schedule of Stock-based Compensation Expense Recognized (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total Stock-based compensation	$ 100,769	$ 194,953	$ 1,455,670	$ 1,217,208
Research and Development Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total Stock-based compensation	38,946	46,584	118,634	194,431
General and Administrative Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total Stock-based compensation	$ 61,823	$ 148,369	$ 1,337,036	$ 1,022,777

Summary of Stock Option Activit

Summary of Stock Option Activity (Details)	9 Months Ended
	Sep. 30, 2021USD ($)$ / sharesshares
Share-based Payment Arrangement [Abstract]
Number of Options, Outstanding, Beginning Balance | shares	5,801,349
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 0.90
Weighted Average Contractual Term, Outstanding Beginning	8 years 6 months 7 days
Aggregate Intrinsic Value Outstanding, Beginning | $	$ 2,773	[1]
Number of Options Outstanding, Granted | shares	1,720,000
Weighted Average Exercise Price, Granted | $ / shares	$ 1.19
Number of Options Outstanding, Exercised | shares	(756,540)
Weighted Average Exercise Price, Exercised | $ / shares	$ 0.48
Number of Options Outstanding, Forfeited | shares	(512,967)
Weighted Average Exercise Price, Forfeited | $ / shares	$ 1.65
Number of Options Outstanding, Ending Balance | shares	6,251,842
Weighted Average Exercise Price, Ending Balance | $ / shares	$ 1
Weighted Average Contractual Term, Outstanding Ending	7 years 3 months 25 days
Aggregate Intrinsic Value Outstanding, Ending | $	$ 460,844	[1]
Weighted Average Exercise Price, Exercisable Ending Balance | shares	5,396,839
Weighted Average Exercise Price, Exercisable Ending Balance | $ / shares	$ 1.02
Weighted Average Contractual Term, Exercisable Ending	7 years 1 month 6 days
Aggregate Intrinsic Value Exercisable, Ending | $	$ 410,777	[1]
[1]	The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock option awards and the closing market price of our common stock as of December 31, 2020 and September 30, 2021, respectively.

Stock-based Compensation (Detai

Stock-based Compensation (Details Narrative)	9 Months Ended
	Sep. 30, 2021USD ($)shares
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Unrecognized compensation cost related to unvested stock options | $	$ 414,571
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition	2 years
Number of shares of common stock are available for future awards	1,000,868
Exercised options to acquire shares of common stock	756,540
Non Employee Directors [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Annual retainer amount for the threshold of stock precluded from selling | $	$ 270,000
Former Chief Executive Officer [Member] | Separation Agreement [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Exercised options to acquire shares of common stock	400,000

Schedule of Warrants Activity (

Schedule of Warrants Activity (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Warrants
Warrants, Ending balance	20,513,145	26,538,593
Weighted Average Price, Ending balance	$ 1.36	$ 1.08
Warrants, Granted		9,200,000
Weighted Average Price, Granted		$ 1.25
Warrants, Exercised	(2,472,573)	(5,680,114)
Weighted Average Price, Exercised	$ 0.91	$ 0.91
Warrants, Expired		(9,545,334)
Weighted Average Price, Expired		$ 0.75
Warrants, Ending balance	18,040,572	20,513,145
Weighted Average Price, Ending balance	$ 1.42	$ 1.36

Schedule of Warrants Outstandin

Schedule of Warrants Outstanding (Details)	Sep. 30, 2021$ / sharesshares
Class of Warrant or Right [Line Items]
Warrants Outstanding	18,040,572
Range One [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding Exercise Price | $ / shares	$ 3.10
Warrants Outstanding	48,387
Expiration Date	Sep. 19, 2022
Range Two [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding Exercise Price | $ / shares	$ 2
Warrants Outstanding	900,000
Expiration Date	Apr. 10, 2023
Range Three [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding Exercise Price | $ / shares	$ 3.10
Warrants Outstanding	462,106
Expiration Date	May 10, 2024
Range Four [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding Exercise Price | $ / shares	$ 3.10
Warrants Outstanding	602,414
Expiration Date	Jul. 25, 2024
Range Five [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding Exercise Price | $ / shares	$ 3.10
Warrants Outstanding	1,064,518
Expiration Date	Nov. 8, 2024
Range Six [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding Exercise Price | $ / shares	$ 1
Warrants Outstanding	3,174,500
Expiration Date	Jul. 17, 2025
Range Seven [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding Exercise Price | $ / shares	$ 0.90
Warrants Outstanding	2,588,647
Expiration Date	Mar. 25, 2024
Range Eight [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding Exercise Price | $ / shares	$ 1.25
Warrants Outstanding	9,200,000
Expiration Date	May 1, 2025

Warrants (Details Narrative)

Warrants (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	May 14, 2020	May 01, 2020
Proceeds from warrant exercises			$ 2,261,336	$ 5,182,402
Warrant [Member]
Number of common stock issued in offering	2,472,573	5,642,114
Warrants to purchase shares of common stock	2,472,573				9,545,334
Proceeds from warrant exercises	$ 2,261,336	$ 5,153,902
Warrant [Member] | Noachis Terra Inc [Member]
Warrants to purchase shares of common stock						9,200,000
Warrants exercise price per share						$ 1.25
Warrant term						5 years
Warrant One [Member]
Warrants to purchase shares of common stock	360,000	760,000		760,000
Warrants exercise price per share	$ 1	$ 1		$ 1
Warrant Two [Member]
Warrants to purchase shares of common stock	2,112,573	4,882,114		4,882,114
Warrants exercise price per share	$ 0.90	$ 0.90		$ 0.90

Short-Term Notes Payable (Detai

Short-Term Notes Payable (Details Narrative) - USD ($)	Jul. 24, 2021	Jul. 24, 2020	Mar. 10, 2019	Sep. 30, 2021	Dec. 31, 2020
Short-term Debt [Line Items]
Short-term notes payable				$ 482,258	$ 228,227
Product Liability Insurance [Member] | Short-term Note Payable [Member]
Short-term Debt [Line Items]
Short-term notes payable			$ 17,688
Debt interest rate			5.69%
Amortization period of debt			11-month period
Debt maturity date			Feb. 14, 2020
Directors' and Officers' Insurance [Member] | Short-term Note Payable [Member]
Short-term Debt [Line Items]
Short-term notes payable	$ 600,169	$ 413,784
Debt interest rate	5.34%	5.39%
Amortization period of debt	10-month period	11-month period
Debt maturity date	May 24, 2022	Jun. 28, 2021

Schedule of Supplemental Balanc

Schedule of Supplemental Balance Sheet Information Related to Leases (Details)	Sep. 30, 2021	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Weighted Average Remaining Lease Term In Years, Operating leases	2 years 8 months 15 days	3 years 5 months 15 days
Weighted Average Discount Rate, Operating leases	5.70%	5.70%

Schedule of Maturities of Opera

Schedule of Maturities of Operating Lease Liabilities (Details)	Sep. 30, 2021USD ($)
Commitments and Contingencies Disclosure [Abstract]
2021	$ 53,059
2022	217,379
2023	169,656
2024	146,719
Total	586,813
Less: Imputed interest	(47,433)
Present value of lease liabilities	$ 539,380

Schedule of Cost Component of O

Schedule of Cost Component of Operating Leases (Details) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Operating lease cost	$ 171,040	$ 169,126
Short-term lease cost	1,159	1,839
Total lease cost	$ 172,199	$ 170,965

Schedule of Supplemental Cash F

Schedule of Supplemental Cash Flow Information Related to Operating Leases (Details) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Operating cash flows from operating leases	$ 170,354	$ 169,264

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative)	May 01, 2020$ / sharesshares	Nov. 30, 2019USD ($)	Nov. 30, 2016USD ($)ft²	Mar. 31, 2021USD ($)$ / sharesshares	Sep. 30, 2021USD ($)$ / shares	Sep. 30, 2020USD ($)$ / sharesshares	May 14, 2020shares
Loss Contingencies [Line Items]
Monthly lease payments | $					$ 170,354	$ 169,264
Amended Lease Agreement [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Monthly lease payments | $					12,870
Payments of rent | $					$ 13,338
Tampa Facility [Member]
Loss Contingencies [Line Items]
Area of office space leased | ft²			2,207
Lease expiry date			Feb. 29, 2020
Period of lease		3 years
Tampa Facility [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Monthly lease payments | $		$ 4,524	$ 4,138
Tampa Facility [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Monthly lease payments | $		$ 4,800	$ 4,392
Range One [Member]
Loss Contingencies [Line Items]
Warrants exercise price per share | $ / shares					$ 3.10
Range Two [Member]
Loss Contingencies [Line Items]
Warrants exercise price per share | $ / shares					$ 2
Warrant [Member]
Loss Contingencies [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares				2,472,573			9,545,334
Payment for Contingent Consideration Liability, Operating Activities | $				$ 542,263
Warrant [Member] | Range One [Member]
Loss Contingencies [Line Items]
Warrants exercise price per share | $ / shares				$ 1
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares				360,000
Warrant [Member] | Range Two [Member]
Loss Contingencies [Line Items]
Warrants exercise price per share | $ / shares				$ 0.90
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares				2,112,573
Warrant One [Member]
Loss Contingencies [Line Items]
Warrants exercise price per share | $ / shares				$ 1		$ 1
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares				360,000		760,000
Noachis Terra Inc [Member] | Warrant [Member]
Loss Contingencies [Line Items]
Warrants exercise price per share | $ / shares	$ 1.25
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	9,200,000
Stock Purchase Agreement [Member] | Twenty Percent Cash Proceeds Exercise Warrants [Member] | Mr. Joseph Hernandez [Member]
Loss Contingencies [Line Items]
Warrants exercise price per share | $ / shares	$ 0.90
Stock Purchase Agreement [Member] | Warrant One [Member] | Mr. Joseph Hernandez [Member]
Loss Contingencies [Line Items]
Percentage of warrant exercise	45.00%
Warrants exercise price per share | $ / shares	$ 1
Stock Purchase Agreement [Member] | Noachis Terra Inc [Member] | Warrant [Member]
Loss Contingencies [Line Items]
[custom:ContingentConsiderationDescriptions]	(i) twenty percent (20%
Percentage of warrant exercise	20.00%
License Agreement [Member]
Loss Contingencies [Line Items]
Royalty expenses | $					$ 30,000
Reimbursement expenses | $					$ 11,739
Agreement expiration term					20 years

Shareholders_ Equity (Details N

Shareholders’ Equity (Details Narrative) - USD ($)	3 Months Ended			9 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2021	Sep. 30, 2020	Mar. 15, 2021	Jan. 28, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares issued upon exercise of stock options				756,540
Gross proceeds from common stock				$ 26,676,392
Warrants outstanding	18,040,572			18,040,572
Series C Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Redemption of preferred shares							26.697
Redemption of preferred stock						$ 5,600,000
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares issued upon exercise of stock options	200,000	556,540		756,540
Gross proceeds from common stock				$ 363,140
Number of shares issued during the period			23,871,338
Warrants outstanding			2,472,573
Gross proceeds from warrants			$ 2,300,000
Common Stock [Member] | ATM Program [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Gross proceeds from common stock			$ 27,800,000
Number of shares issued during the period			21,398,765